首页> 外文期刊>Case Reports in Ophthalmological Medicine >Macular Oedema in Idiopathic Macular Telangiectasia Type 1 Responsive to Aflibercept but Not Bevacizumab
【24h】

Macular Oedema in Idiopathic Macular Telangiectasia Type 1 Responsive to Aflibercept but Not Bevacizumab

机译:黄斑水肿在特发性黄斑毛细血管扩张1型中对Aflibercept敏感但对贝伐单抗无反应

获取原文
           

摘要

We report a patient with macular oedema due to type 1 macular telangiectasia responding to intravitreal aflibercept injection. A 51-year-old man was diagnosed with type 1 idiopathic macular telangiectasia (IMT) in the right eye. The macular oedema was refractory to initial treatment with intravitreal bevacizumab and argon laser photocoagulation. The patient was then treated with intravitreal aflibercept injections, following which the macular oedema was completely resolved and his vision was significantly improved. Intravitreal aflibercept injection appears to improve vision and reduce persistent macular oedema secondary to type 1 IMT and demonstrated promising anatomical and visual outcomes.
机译:我们报告了由于玻璃体内阿柏西普注射引起的1型黄斑毛细血管扩张引起的黄斑水肿患者。一名51岁的男性被诊断出右眼患有1型特发性黄斑毛细血管扩张(IMT)。黄斑水肿对于玻璃体内贝伐单抗和氩激光光凝的初始治疗是难治的。然后用玻璃体腔注射阿柏西普注射液治疗该患者,此后黄斑水肿完全消失,视力得到明显改善。玻璃体腔注射阿柏西普似乎可以改善视力,并减轻继发于1型IMT的持续性黄斑水肿,并显示出有希望的解剖学和视觉结果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号